A review of the records reveals the member to be an adolescent male with a birth date of 06/08/1998. The member has a diagnosis of Type 1 Diabetes Mellitus. The member’s treating provider, Rebecca Fannin, MD has been prescribing the member Novolog 100 unit/ml cartridge. The carrier has denied coverage of Novolog 100 unit/ml cartridge as not medically necessary. There is a letter from the carrier to the member dated 03/23/2016 which states in part: “The medical necessity criteria for coverage have not been met in this case. As a result, we are unable to cover the services and apply the allowable to your deductible. In this case, there is no documentation to show that Brandon has tried and failed Humalog. Additionally, the required step …show more content…
On Saturday, 02/20/2016, we attempted to pick up the prescription, but were told by Walgreen’s that is was denied by Humana. This was our first attempt to purchase this medication since our group (HM Graphics, group # 636872) moved to Humana on 01/01/2016. Neither Humana nor Walgreen’s contacted us about the denial, so by the time we needed to pick up the medication it was too late to resolve the issue with Humana, since the proper department was closed. Our hands were tied and we were forced to purchase the drug at full cost because of the lack of communication. Because our son needed the medication THAT DAY, we paid out of packet for the full cost of $673.00 for the medication. It wasn’t until Monday, 02/22/2016 that we found out that Humana put a Step Therapy requirement on the medication, and since we haven’t purchased the drug through Humana to this point, we had no idea that this would ever be a problem.” Final External Review Decision: The carrier’s decision in denying coverage for the requested prescription Novolog 100 unit/ml cartridge was appropriate. There is insufficient medical record documentation to determine whether Novolog is medically necessary for the treatment of this member’s …show more content…
The member has an approximate 8 year 6 month history of Type 1 Diabetes that is managed with continuous subcutaneous insulin infusion (pump) therapy. There are only a few medical records provided for review. However, a visit note dated in January of 2016 notes that the member is on pump therapy. It does not state which insulin was prescribed at that time. However, pumps typically use a short-acting insulin analog. Per the appeal letter from the member’s father, the member has always been on Novolog and, after they switched insurance plans, it wasn’t until they went to pick up the Novolog from the pharmacy that they learned the medication was denied. Since the member needed it, they paid for the full prescription out-of-pocket (presumably a 3-month supply based on the price and the member’s insulin dose) and are now requesting for retrospective coverage. According to the member’s insurance plan, the preferred short-acting insulin analog of choice is Humalog. They note that Novolog is covered if “the member has had previous treatment, contraindication, or intolerance to Humalog.” It further states that this needs to be documented by filling out a specific form. Per the records submitted, no such documentation of “previous treatment, contraindication, or intolerance to Humalog” had been
The carrier has denied coverage of the replacement insulin pump (E0784), as the requested service does not meet criteria for medical necessity. There is a letter from the carrier to the member dated 04/27/2016, which states in part:
15,2017 Contacted Ms. Maxine Bargelle on her condition since leaving the hospital and have she found any money for the eye drops yet . Ms.Maxine stated she is still having financial problems and can not get any of the medications until April 3,2017 when she receive hers SSI check. Ms. Maxine explained she had so many medical issues and no family members to help her out. I let Ms. Maxine know she will reach out to her eye doctor Bruce Cohen MD for free eye drops samples.And her primary care doctor Philip Conway, MD for samples of her medications to get her over until her check comes in April 3,2017.I provided Ms. Maxine my name again and telephone number to DHSS if she has any incidents before my visit Monday 20,2017.
The arrangement did not work, as the son-in-law used Ms. Inez insurance for his diabetic supplies. She showed me her medications that were in his name.
The patient refused to sign the self pay estimate; because she feels that she should have been contacted before the having the test, and at the point she would not have had the test performed.
Samantha is a 47-year-old female who suffers from RR multiple sclerosis (G35), along with a history of pelvic fracture, neoplasm of pituitary gland and craniopharyngeal duct, vitamin D deficiency, and chronic fatigue. Samantha has tried and failed various treatments including betaseron, copaxone, tecfidera, and rebif, all have provided her with minimal remission from her symptoms. The denial states Aubagio is not on the plan’s formulary. We are requesting an exception for the Aubagio to be covered or added to the plan’s formulary. Samantha is currently stable on Aubagio with no ill side effect, therefore it would be ill advised to deny Samantha coverage for a treatment that is currently controlling her symptoms. Forcing her to change to a medication
The requested prescription medication, Harvoni 90mg - 400mg, would be medically necessary for the treatment of this member’s condition, however, at this time, the member does not meet the medical necessity criteria for coverage due to his continued use of alcohol.
Entyvio was requested to treat regional enteritis of unspecified site (Crohn's disease) not responsive to Humira. The Plan denied the request for an exception because the enrollee tried only one of the drugs covered by the
The prescription do not always comply with all legal requirements, i.e. dated and signed and handwriting in not always legible,
Recent refills (meds will not be eligible for refill for next 90 days, as the Rx was just recently requested)
Problem: patient can not afford medication; therefore, the patient is not taken medication as prescribed by doctor.
Mr. H refused to take his insulin dose and his daughter was worried. In fact, Mr. H was much more worried because he knew that two of his daughters were diagnosed with diabetes and he did not want them to suffer. Mr. H continued to resist taking his insulin dose and other medications. In August 13, 2005, Mr. H presented to the Emergency Department complaining of
Last Monday, I was taken to Urgent Care where I found out I had the flu. Before the doctor could ask, I requested a script for Tamiflu. Immediately the urgent care doctor wrote a script for the generic brand which I caught before leaving the office. My order for Tamiflu was emailed to my pharmacy (CVS) and needless to say, I did not get. The Pharmacist, filled my prescription with the generic brand despite the doctor’s note for brand. I then requested brand and I was also told “All CVS pharmacies do not keep Tamiflu in stock because it’s too
This article discusses how Medicare Carriers and Fiscal Intermediaries use coverage determinations to establish medical necessity. When the condition(s) of a patient are expected to not meet medical necessity requirements for a test, procedure, or service, the provider has the obligation under the Beneficiary Notices Initiative to alert the Medicare beneficiary prior to rendering the service. The Medicare beneficiary is notified via the Advance Beneficiary Notice (ABN) (see page 235 in Appendix B).
Brooke is a 47-year-old female who suffers from a long history of Sheehan’s syndrome (E23.0). Brooke’s symptoms include onset growth hormone deficiency was brought on by a pituitary infarction (Sheehan’s Syndrome) resulting from post-partum massive hemorrhaging. Brooke would like to stay on the medications that have proven to work for her, which are the Genotropin Miniquick (DAW), Solu-cortef (DAW), and Vivelle (DAW). To switch to other medications requires months of physical adjustments, additional blood tests and lab work to find a new balanced level of all the medications. Brooke has learned from her doctors that patented drugs cannot be the same in order to be patented drugs. Denying coverage of a therapy when a patient has a significant
“Claim number 201602083184074 (Genomic Health Inc.) was denied as services that are experimental/investigational are not a covered benefit. According to Humana's medical coverage policy, while the Oncotype DX assay may eventually have a role in making treatment decisions about